Psoriasis News and Research

Latest Psoriasis News and Research

Researchers mix active drug and placebo to maximize drug benefits for efficient treatment

Researchers used the placebo effect to successfully treat psoriasis patients with one quarter to one half of their usual dose of a widely used steroid medication, according to an early study published online today in the journal Psychosomatic Medicine.

23 Dec 2009

Prasco Laboratories to market Stiefel Laboratories' Clobetasol Propionate Foam

Prasco Laboratories announced today that they have signed a distribution and supply agreement with Stiefel Laboratories, Inc., a GlaxoSmithKline company, for Clobetasol Propionate Foam 0.05%, the latest product in Prasco's line of authorized generics. Under the terms of the agreement, Prasco will market and distribute Clobetasol Propionate Foam 0.05% in 50g and 100g canisters in the U.S. under the Prasco label.

22 Dec 2009

GSK receives European CHMP positive opinion for Revolade

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

18 Dec 2009

Ligand Pharmaceuticals, Neurogen revise merger agreement

Ligand Pharmaceuticals Incorporated and Neurogen Corporation announced today they have amended their merger agreement to increase the merger consideration payable

18 Dec 2009

Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. and Almirall, S.A. (ALM.MC) today announced that they have entered an agreement to develop, market and distribute LAS100977 in the United States.

17 Dec 2009

DNA reveals earliest proven case of leprosy, Turin Shroud not from Jesus-era Jerusalem

The DNA of a 1st century shrouded man found in a tomb on the edge of the Old City of Jerusalem has revealed the earliest proven case of leprosy. Details of the research will be published December 16 in the PloS ONE Journal.

16 Dec 2009

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Celgene Corporation announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). This was a 352-patient, multi-center study in which patients received either 10mg, 20mg or 30mg of apremilast twice per day (BID), or placebo.

15 Dec 2009

Bio-Quant becomes wholly-owned subsidiary of NexMed

NexMed, Inc., a developer of products based on the NexACT® technology, today announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA. Upon closing, Bio-Quant became a wholly-owned subsidiary of NexMed.

15 Dec 2009

Perrigo files Abbreviated New Drug Application for Clobex Spray

Perrigo Company today announced that it has filed an Abbreviated New Drug Application for Clobetasol Propionate Topical Spray, 0.05%, a generic form of Clobex® Spray.

10 Dec 2009

Specialty pharmaceutical market: Treatment patterns and product performance

IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the wide-scale availability of its advanced analytical offering, IMS Specialty Market Dynamics™, which delivers the most complete view of treatment patterns and product performance in the rapidly growing specialty pharmaceutical market.

8 Dec 2009

Study: Besides nerves, skin has a unique sensory system

The human sensory experience is far more complex and nuanced than previously thought, according to a groundbreaking new study published in the December 15, 2009 issue of the journal Pain (http://www.painjournalonline.com/article/S0304-3959%2809%2900526-0/abstract).

8 Dec 2009

Biogen Idec's BG-12 achieves key milestones in clinical trials for MS and RA

Biogen Idec today announced that its oral compound BG-12 (dimethyl fumarate) achieved key milestones in clinical trials for multiple sclerosis (MS) and rheumatoid arthritis (RA).

8 Dec 2009

Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced preliminary data for the company’s PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis.

1 Dec 2009

European Patent Office grants patent EP1392642 for 4SC AG's lead auto-immune compound

4SC AG, a drug discovery and development company, today announced that the European Patent Office has granted patent EP1392642, which covers its lead auto-immune compound 4SC-101.

1 Dec 2009

Completion of Phase I study of CPSI-2364 announced by Cytokine PharmaSciences

Cytokine PharmaSciences, Inc. today announced the completion of a Phase I study of CPSI-2364, its orally active, small-molecule inhibitor of the production of TNF-alpha and other pro-inflammatory cytokines.

1 Dec 2009

Advitech announces merger operations with Botaneco Specialty Ingredients

Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announced today that, further to the consolidation of its common shares on a 8-for-1 basis (the "Consolidation"), the TSX Venture Exchange Inc. (the "TSX-V") has approved the release from escrow of the previously announced acquisition of all the issued and outstanding shares of Botaneco Specialty Ingredients Inc.

27 Nov 2009

TSX Venture Exchange approves Advitech's issued and outstanding common shares

Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announced today that the TSX Venture Exchange Inc. (the "TSX-V") approved the previously announced consolidation of its issued and outstanding common shares on the basis of a ratio of eight pre-Consolidation shares for every one post-Consolidation share (the "Consolidation") and that the common shares of Advitech will be traded on a post-Consolidation basis starting November 26, 2009.

26 Nov 2009

GIS scientists publish the first genetic historical map of Han Chinese

The first genetic historical map of the Han Chinese, the largest ethnic population in the world, as they migrated from south to north over evolutionary time was published online today by the American Journal of Human Genetics by scientists at the Genome Institute of Singapore (GIS).

26 Nov 2009

Dermatologists express strong interest in Stelara, despite concerns

BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research project tracking the launch of Centocor Ortho-Biotech's Stelara, from product launch through the first six months of availability. Each wave of the report provides quantitative information from 75 unique Dermatologists and qualitative information from a subset of 20.

26 Nov 2009

Incyte enters into collaboration and license agreement with Novartis

Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.

25 Nov 2009